France's Cytheris banks $15M for immunotherapy work

Paris-based Cytheris has rounded up $15 million in its fourth venture round, with the money earmarked for new R&D work on the developer's immune modulation program.

"This financing provides us with the resources to aggressively advance CYT107 through clinical trials, particularly in the HIV and hepatitis markets," said Michel Morre, the president and CEO of Cytheris. "After demonstrating the quality of IL-7 induced immune reconstitution in most patients treated in our HIV studies, we are now focusing these investigations on showing that repeated cycles of IL-7 can induce long term or definitive immune restoration, while our HCV and HBV studies are aimed at documenting the production of specific antiviral T cells, potentially offering long term protection."

A new investor, France's CDC Entreprises, participated in the round along with existing investors Bioam Gestion, Caisse de dépôt et Placement du Québec, CDC Innovation, Crédit Agricole Private Equity, and Forbion Capital Partners from The Netherlands.

- here's the Cytheris release

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.